The investigators propose a parallel group randomized clinical trial of intrapartum nipple stimulation versus exogenous oxytocin infusion for nulliparous women undergoing induction of labor near term. The central hypothesis is that intrapartum nipple stimulation to induce labor increases spontaneous vaginal delivery, improves patient-centered outcomes such as childbirth satisfaction, labor agentry, and pain scores, and reduces adverse neonatal and maternal outcomes in nulliparous women. The investigators will pursue the following specific aims: 1) Assess the effectiveness of intrapartum nipple stimulation on the rate of spontaneous vaginal delivery in nulliparous women, 2) Breastfeeding as the sole source of nutrition at time of maternal hospital discharge (Primary Aims); 3) Maximal percent newborn weight loss during the birth hospitalization within 72 hours of life, 4) Determine the effect of intrapartum nipple stimulation on the rate of adverse maternal and neonatal outcomes, 5) Determine the impact of intrapartum nipple stimulation on patient-centered outcomes and 6) In a sub-cohort of women who are enrolled in the trial, investigators will measure the change in oxytocin concentration from baseline to time at which patient achieves a regular contraction pattern.
Primary Objectives 1. To determine whether intrapartum nipple stimulation therapy with or without synthetic oxytocin changes the likelihood of achieving a spontaneous vaginal delivery compared to receipt of synthetic oxytocin infusion without nipple stimulation to induce labor. 2. Breastfeeding as the sole source of nutrition at time of maternal hospital discharge Secondary Objectives (if applicable) The secondary objectives are as follows: 1. Determine whether intrapartum nipple stimulation therapy with or without synthetic oxytocin changes the likelihood of achieving a spontaneous vaginal delivery compared to receipt of synthetic oxytocin infusion without nipple stimulation to induce labor. 2. Determine if women who perform intrapartum nipple stimulation to induce labor have differences in other obstetric and maternal outcomes 3. Determine if women who perform intrapartum nipple stimulation report differences in pain scores during labor, labor agentry and satisfaction scores, postpartum depression scores, and breastfeeding success compared to women who receive only intrapartum exogenous oxytocin infusion. 4. Determine if women who perform intrapartum nipple stimulation to induce labor have similar fetal and neonatal outcomes compared to women who receive only intrapartum exogenous oxytocin infusion. 5. Maximal percent newborn weight loss during the birth hospitalization within 72 hours of life 6. At Yale, to measure the change in oxytocin concentration from baseline over the course of labor induction in patients undergoing induction of labor via intrapartum nipple stimulation versus continuous exogenous oxytocin infusion. 7. At Yale, to measure circulating plasma and urine concentrations of proteins, microRNA, and small molecules using unbiased "omics" approaches, comparing patients undergoing induction of labor via intrapartum nipple stimulation versus continuous exogenous oxytocin infusion, un-ripened/unlabored control patients, and patients in spontaneous labor.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
988
Participants randomized to the intrapartum nipple stimulation will use electric breast pump or nipple stimulate by hand (if preferred) (intervention) to induce labor for at least 2 hours
Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to induce labor as current standard of care
Yale New Haven Hospital
New Haven, Connecticut, United States
RECRUITINGNorthwestern Memorial Hospital
Chicago, Illinois, United States
ACTIVE_NOT_RECRUITINGWeill Cornell Medicine
New York, New York, United States
RECRUITINGSpontaneous vaginal delivery
Spontaneous vaginal delivery will be defined as delivery that occurs without the use of forceps, vacuum, or cesarean
Time frame: At delivery
Breastfeeding as the sole source of nutrition (BSSN)
Number of participants using breastfeeding as the sole source of nutrition (BSSN) at time of maternal discharge or 72 hours of life (whichever is sooner)
Time frame: up to 72 hours following delivery
Operative vaginal delivery
Delivery with the assistance of forceps or vacuum, and indication
Time frame: At delivery
Cesarean delivery
Delivery by cesarean section
Time frame: At delivery
Labor induction duration
Time interval from randomization to delivery
Time frame: At delivery
Number of Participants with Postpartum hemorrhage
Cumulative blood loss of ≥1,000 mL within 24 hours after the birth process
Time frame: From delivery to 24 hours postpartum
Number of Participants with Severe Postpartum hemorrhage
Transfusion; non-elective hysterectomy; use of ≥2 uterotonic medications other than oxytocin; other interventions such as uterine compression sutures, uterine artery ligation or embolization, hypogastric artery ligation, balloon tamponade
Time frame: From delivery to 24 hours postpartum
Number of participants with suspected infection
Suspected intraamniotic infection, intrapartum chorioamnionitis, or postpartum endometritis (defined as maternal fever ≥38° Fahrenheit with planned or initiated administration of therapeutic antibiotics) after randomization and prior to delivery hospitalization discharge
Time frame: 3-7 days postpartum
Lactational mastitis
Subject-reported occurrence of lactational mastitis
Time frame: After delivery to 12 weeks postpartum
Number of maternal deaths
Incidence of maternal death prior to, during, or post delivery
Time frame: immediately prior to up to immediately post delivery
Maternal Intensive Care Unit admission
Any admission to the Intensive Care Unit after delivery and prior to delivery hospitalization discharge
Time frame: 3-7 days postpartum
Neonatal Intensive Care Unit admission
Any admission to the Neonatal Intensive Care Unit From birth to birth hospitalization discharge or 28 days after birth, whichever is earlier
Time frame: up to 28 days following birth
Neonatal Apgar score ≤3 at 5 minutes of life
The Neonatal Apgar score is scored from 0 to 10. A 5-minute Apgar score of 0-3 correlates with neonatal mortality in large population studies.
Time frame: At 5 minutes after birth
Umbilical acidemia
Umbilical cord arterial pH \<7.0 or base excess \>12 mmol/L; or umbilical cord venous pH \<7.0 or base excess \>12 mmol/L if arterial blood sample not available
Time frame: At delivery
Composite neonatal severe morbidity measure
Intrapartum fetal death or neonatal death; cardiorespiratory support within first 72 hours of life; neonatal encephalopathy; seizures; hypothermic treatment (cooling); sepsis; pneumonia; major birth injury; meconium aspiration syndrome; intracranial hemorrhage or subgaleal hemorrhage; or hypotension requiring pressor support
Time frame: up to 28 days following delivery
Percent newborn weight loss
Maximal percent newborn weight loss in kilograms(kg)
Time frame: At 72 hours of life or birth hospitalization discharge, whichever is earlier
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.